David Murdock, MD
Psychiatry · Lake Charles, LANPI 1508830316
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Sanofi Pasteur Inc. at 57.2% of the total. Reporting peaked in 2020 at $10,365 and has fallen 98.2% since, to $187 in 2025. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 413 payments — averaging $43.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$10K
- AbbVie$1K
- Johnson & Johnson$823
- Indivior Inc.$654
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$608
- Neurocrine Biosciences, Inc.$552
- plus $4K from 22 others
What the payments were for
- Consulting fees$9,15651%
- Travel & lodging$8605%
- Food & beverage$7,98144%
- Education$1201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 12 | $10,365 |
| AbbVie | 78 | $1,285 |
| Johnson & Johnson | 45 | $823 |
| Indivior Inc. | 39 | $654 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $608 |
| Neurocrine Biosciences, Inc. | 24 | $552 |
| Axsome Therapeutics, Inc. | 20 | $533 |
| Teva Pharmaceuticals USA, Inc. | 23 | $466 |
| Otsuka America Pharmaceutical, Inc. | 20 | $457 |
| Alkermes, Inc. | 24 | $453 |
| Lundbeck LLC | 23 | $425 |
| Sunovion Pharmaceuticals Inc. | 19 | $280 |
| Vanda Pharmaceuticals Inc. | 12 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $244 |
| Noven Therapeutics, LLC | 10 | $202 |
| Corium, LLC | 6 | $96 |
| LSI Solutions Inc | 1 | $85 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Supernus Pharmaceuticals, Inc. | 2 | $53 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Gilead | 2 | $40 |
| Eisai Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $22 |
| Braeburn Inc. | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $19 |
| Sage Therapeutics, LLC | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,117 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $234,471 |
| AustedoDeutetrabenazine | 47 | $187,606 |
| Invega SustennaPaliperidone Palmitate | 50 | $136,054 |
| VraylarCariprazine Hcl | 83 | $134,548 |
| Austedo XrDeutetrabenazine | 15 | $111,596 |
| TrintellixVortioxetine Hydrobromide | 193 | $105,764 |
| CaplytaLumateperone Tosylate | 45 | $71,849 |
| AuvelityDextromethorphan Hbr/Bupropion | 66 | $67,937 |
| LybalviOlanzapine/Samidorphan Malate | 20 | $30,444 |
| RexultiBrexpiprazole | 18 | $28,678 |
| BelsomraSuvorexant | 24 | $10,322 |
| Lurasidone Hcl | 49 | $8,427 |
| Paliperidone ErPaliperidone | 33 | $7,607 |
| Divalproex Sodium ErDivalproex Sodium | 58 | $5,028 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $466 | $299,20262 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $552 | $234,47127 claims |
| Johnson & JohnsonInvega Sustenna | $823 | $136,05450 claims |
| AbbVieVraylar | $1,285 | $134,54883 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $244 | $110,736206 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $608 | $71,84945 claims |
| Axsome Therapeutics, Inc.Auvelity | $533 | $67,93766 claims |
| Alkermes, Inc.Lybalvi | $453 | $30,44420 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $457 | $28,67818 claims |
| MerckBelsomra | $12 | $10,32224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Lake Charles
- Patrick HayesLake Charles$837K
- Jayendra PatelLake Charles$13K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Roger BrownMandeville$216K
- Abdul KhanBaton Rouge$156K
- William ColombMandeville$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.